Amidst a resurgence of COVID-19 cases across the United States, pharmaceutical company Gilead Sciences, Inc. has announced a voluntary recall of its antiviral drug Veklury, commonly known as remdesivir, in cooperation with the U.S. Food & Drug Administration (FDA).
The recall comes after the discovery of glass particles in vials of the medication, raising concerns about patient safety at a time when the drug’s importance in treating severe COVID-19 cases is once again being underscored.
